Table 4 Univariate analysis of relapse
From: RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker
Characteristic | Hazard ratio | 95% CI | P -value |
|---|---|---|---|
Age at diagnosis | |||
<12 months | Reference | ||
⩾12 months | 12.5 | 2.8–55.3 | <0.001 |
Sex | |||
Male | Reference | ||
Female | 1.0 | 0.4–2.9 | 0.972 |
Stage | |||
1/2/3/4S | Reference | ||
4 | 14.3 | 4.0–51.0 | <0.001 |
MYCN | |||
Non-amplified | Reference | ||
Amplified | 7.2 | 2.6–20.0 | <0.001 |
Serum RASSF1A | |||
Unmethylated | Reference | ||
Methylated | 6.8 | 2.4–19.1 | <0.001 |
